Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults

Pneumococcal vaccination coverage and adherence to recommended dosing schedules in adults: a repeated cross-sectional study of the INTEGO morbidity registry

(2023) Arne Janssens et al.   BMC PUBLIC HEALTH

Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain

(2023) David Cantarero et al.   Vaccine

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine

(2023) Estelle Méroc et al.   Microorganisms

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting

(2023) Mikkelsen Malene B et al.   Cost Effectiveness and Resource Allocation

Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly

(2022) Shu-ling Hoshi et al.   VACCINE

Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease

(2022) Diana Mendes et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23

(2022) Jens Olsen et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population

(2022) Barbara Polistena et al.   Vaccines

Belgian population norms for the EQ-5D-5L, 2018

(2021) Lisa Van Wilder et al.   QUALITY OF LIFE RESEARCH

The impact of multimorbidity patterns on health-related quality of life in the general population: results of the Belgian Health Interview Survey

(2021) Lisa Van Wilder et al.   QUALITY OF LIFE RESEARCH

Mortality and readmission in the year following hospitalization for pneumonia among US adults

(2021) Ahuva Averin et al.   RESPIRATORY MEDICINE

Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis

(2021) Hao Chen et al.   Scientific Reports

Pneumococcal vaccination prevented severe LRTIs in adults: a causal inference framework applied in registry data

(2021) Pavlos Mamouris et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective

(2020) Lieven Annemans et al.   VALUE IN HEALTH

Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations

(2019) A. Løchen et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions

(2019) Tinevimbo Shiri et al.   VALUE IN HEALTH

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design

(2018) John M McLaughlin et al.   CLINICAL INFECTIOUS DISEASES

Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection

(2018) Sophie Marbaix et al.   PLoS One

Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease

(2016) G. J. HUGHES et al.   EPIDEMIOLOGY AND INFECTION

Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium

(2015) Johan Flamaing et al.   BMC Family Practice

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

(2015) Marie-Josée J. Mangen et al.   EUROPEAN RESPIRATORY JOURNAL

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

(2015) Marc J.M. Bonten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community

(2015) Bernhard Ultsch et al.   PHARMACOECONOMICS

The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project

(2014) Carla Truyers et al.   BMC Medical Informatics and Decision Making

Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009–2011

(2014) J Verhaegen et al.   Eurosurveillance

Pneumococcal pneumonia and the risk of acute coronary syndrome: A population-based cohort study

(2013) Chun-Cheng Wang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England

(2012) Albert Jan van Hoek et al.   JOURNAL OF INFECTION

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults

(2010) Neil French et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and economic burden of community-acquired pneumonia among adults in Europe

(2010) T Welte et al.   THORAX